It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?
January 4, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
- Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan
December 28, 2018
- Kyorin, Hebrew University Link Arms in Respiratory Drug Development
December 28, 2018
- Ono Files Heart Failure Drug Ivabradine in Japan
December 28, 2018
- Chugai Obtains Approval of First Dual-Function Gene Panel Test
December 28, 2018
- Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline
December 27, 2018
- Crestor Generics of Nichi-Iko, Towa Now Have Full Indications
December 27, 2018
- Xofluza Most Heavily Promoted Drug for GP in October: Anterio
December 27, 2018
- First Cancer Gene Panel Test Approved in Japan: Sysmex
December 27, 2018
- Japan Vaccine to Transfer Business to Daiichi Sankyo, GSK in April
December 27, 2018
- Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
December 26, 2018
- Sumitomo Dainippon to Merge Authorized Generic Units
December 26, 2018
- Fuji Yakuhin Files Hyperuricemia Candidate Dotinurad
December 26, 2018
- Fujifilm, MIT Launch Research Project on Oligonucleotide DDS
December 26, 2018
- INCJ Makes Further Investment in NapaJen Pharma
December 26, 2018
- RaQualia’s Tegoprazan Sublicensed to Vietnam’s Vimedimex
December 26, 2018
- Some Drug Makers Stop Distributing 2019 Calendars with Revised JPMA Code of Practice Set to Take Effect in January
December 25, 2018
- Takeda Completes M&A Bridge Re-Financing
December 25, 2018
- Mundipharma Files for Japan Approval of Anesthetic Remimazolam
December 25, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…